Fill out the form to get a free trial:
1Institute of Pathology, Charité Campus Mitte
Fill out the form to get a free trial:
For development of RNA interference (RNAi)-based therapies, a novel strategy was developed, transkingdom RNAi (tkRNAi). This technology uses non-pathogenic bacteria to produce and deliver therapeutic short hairpin RNA (shRNA) into target cells. Here, tkRNAi was successfully applied for reversal of classical ABCB1-mediated multidrug resistance (MDR) of cancer cells.
Lage, H., Krühn, A. Bacterial Delivery of RNAi Effectors: Transkingdom RNAi. J. Vis. Exp. (42), e2099, doi:10.3791/2099 (2010).
RNA interference (RNAi) represents a high effective mechanism for specific inhibition of mRNA expression. Besides its potential as a powerful laboratory tool, the RNAi pathway appears to be promising for therapeutic utilization. For development of RNA interference (RNAi)-based therapies, delivery of RNAi-mediating agents to target cells is one of the major obstacles. A novel strategy to overcome this hurdle is transkingdom RNAi (tkRNAi). This technology uses non-pathogenic bacteria, e.g. Escherichia coli, to produce and deliver therapeutic short hairpin RNA (shRNA) into target cells to induce RNAi. A first-generation tkRNAi-mediating vector, TRIP, contains the bacteriophage T7 promoter for expression regulation of a therapeutic shRNA of interest. Furthermore, TRIP has the Inv locus from Yersinia pseudotuberculosis that encodes invasin, which permits natural noninvasive bacteria to enter β1-integrin-positive mammalian cells and the HlyA gene from Listeria monocytogenes, which produces listeriolysin O. This enzyme allows the therapeutic shRNA to escape from entry vesicles within the cytoplasm of the target cell. TRIP constructs are introduced into a competent non-pathogenic Escherichia coli strain, which encodes T7 RNA polymerase necessary for the T7 promoter-driven synthesis of shRNAs. A well-characterized cancer-associated target molecule for different RNAi strategies is ABCB1 (MDR1/P-glycoprotein, MDR1/P-gp). This ABC-transporter acts as a drug extrusion pump and mediates the "classical" ABCB1-mediated multidrug resistance (MDR) phenotype of human cancer cells which is characterized by a specific cross resistance pattern. Different ABCB1-expressing MDR cancer cells were treated with anti-ABCB1 shRNA expression vector bearing E. coli. This procedure resulted in activation of the RNAi pathways within the cancer cells and a considerable down regulation of the ABCB1 encoding mRNA as well as the corresponding drug extrusion pump. Accordingly, drug accumulation was enhanced in the pristine drug-resistant cancer cells and the MDR phenotype was reversed. By means of this model the data provide the proof-of-concept that tkRNAi is suitable for modulation of cancer-associated factors, e.g. ABCB1, in human cancer cells.
1) Bacterial Delivery of shRNAs
2) Representative Results
If the protocol is performed correctly, the results should be comparable to the ones shown below.
Figure 1 shows a human gastric carcinoma cell three hours after bacterial treatment (a) in comparison to an untreated cell (b). Around the nucleus of the treated cell, bacteria can be detected.
Figure 1: Fluorescent microscopy Human gastric carcinoma cell after bacterial treatment (1:500) and an untreated human gastric carcinoma cell as control, DAPI-staining, DAPI bandpass filter (Λem = 640 nm), 40x objective .
Quantitative real-time RT PCR
In figure 2 a down regulation of MDR1 mRNA of about 70 % (black beam) can be seen after treatment with the therapeutic bacteria. Parental cells serve as a positive control due to the lack of MDR1 overexpression. The cell line 257RDB p170 containing a plasmid expressing anti-MDR1 shRNAs s taken as direct comparison of the transkingdom RNAi technology to other RNAi silencing strategies. The untreated resistant cell line EPG85-257RDB overexpressing MDR1, the same cell line treated with bacteria lacking the shRNA expressing plasmid, and this cell line treated with therapeutic bacteria carrying a plasmid expressing anti-MRP2 shRNAs were taken as positive controls.
Figure 2: Quantitative real-time RT PCR MDR1 mRNA expression after treatment with therapeutic E. coli ceq221 expressing anti-MDR1 shRNAs (MOI 1 : 500). Normalization was performed using the housekeeping gene aldolase. The MDR1/aldolase ratio of untreated cells of the cell line EPG85-257RDB were set 100 %. P-values were calculated using the student's t-test (* = p<0.05, ** = p<0.005, *** = p<0.001).
Western blot analysis
Figure 3 reveals that the MDR1 down regulation also took place on protein level after bacterial treatment. It shows the lacking MDR1 expression of the drug sensitive parental cell line (EPG85-257P), the MDR1 expression of the untreated drug resistant cell line (EPG85-257RDB) and the MDR1 expression of the treated sample. A clear down regulation of MDR1 of the bacterially treated cells can be observed.
Figure 3: Western blot analysis. MDR1 expression levels of the untreated drug-sensitive EPG85-257P, the untreated drug-resistant EPG-257RDB, and of EPG85-257RDB after co-incubation with E. coli ceq221 + p43 MDR1. Primary Ab C219 1:100, and anti-actin 1:5 000, secondary Ab anti-mouse 1:10 000.
Functional analysis like the cytotoxicity assay shown in figure 4 are also indicators for the functioning of the transkingdom RNAi. The parental cell line and the cell line containing an anit-MDR1 shRNA expressing plasmid do not show any resistance to daunorubicin. The resistant cell line EPG85-257RDB and two further controls do not show significant changes in resistance in comparison to the sample treated with anti-MDR1 shRNA expressing bacteria where the resistance to Daunorubicin could be reversed by about 90 %.
Figure 4: Cytotoxicity assay. Drug-specific IC50-values determined by a cytotoxicity assay for cell survival. P-values were calculated using the student's t-test (* = p<0.05, ** = p<0.005, *** = p<0.001).
Anthracycline accumulation assay
According to the lowered resistance of bacterially treated samples (figure 4), the anthracycline accumulation of anti-MDR1 shRNA treated cells is increased by about 90 % as shown in figure 5. The parental cell line and the cell line 257RDB p170 show a strong daunorubicin accumulation up to 100 %. The resistant variant shows rarely any accumulation. Cells treated with anti-MDR1 shRNA expressing bacteria show an anthracyline accumulation increase of 90 %.
Figure 5: Anthracycline accumulation assay. Anthracycline accumulation of carcinoma cells 6 days after bacterial treatment measured by flow cytometry. P-values were calculated using the student's t-test (* = p<0.05, ** = p<0.005, *** = p<0.001).
The cell number seeded for infection and the corresponding MOI used, critically depend on the cell lines under observation and their speed of growth. To find optimal cell numbers for seeding, pre-experiments to determine the speed of growth are strongly recommended. Besides this, different MOIs should be tested due to the limited extend to which the cells can stand the bacterial invasion without dying of stress. The optimal point of time where the down regulation of the gene under observation may vary. It is recommended to perform experiments over a certain period of time to find the optimal conditions.
No conflicts of interest declared.
Work was supported by grant no. 01GU0615 of the "Bundesministerium für Forschung und Technologie (BMBF).
|Amphotericin B||Biochrom AG||A2612|
|Dulbecco's Phosphate Buffered Saline-PBS (10 x)||Invitrogen GmbH||14080048|
|E. coli ceq221||Cequent Pharmaceuticals Inc.||No catalogue available, direct order|
|Penicillin/Streptomycin||Invitrogen GmbH||Contains 5,000 units of penicillin (base) and 5,000 μg of streptomycin (base)/ml utilizing penicillin G (sodium salt) and streptomycin sulfate in 0.85% saline.|
|Sodium chloride||Merck KgaA||1064060500|
|Yeast Extract||Difco Laboratories||212750|
You must be signed in to post a comment. Please sign in or create an account.